Navigation Links
CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster Expanded Lab Operations
Date:11/1/2012

BOSTON, Nov. 1, 2012 /PRNewswire/ -- Cartagenia, the world leader in providing genetic labs and clinicians software-based workflow support for variant assessment, lab reporting, and integration of diagnostic knowledge-bases, announced today that it has signed a license agreement for the Cartagenia BENCHlab CNV platform with CombiMatrix Corporation (Nasdaq: CBMX), a molecular diagnostics company.

Irvine, CA-based CombiMatrix is a CLIA-certified and CAP-accredited, publicly-owned commercial clinical laboratory offering DNA-based genomic testing services in the areas of prenatal and pediatric developmental disorders and oncology. CombiMatrix has established itself as an industry leader in microarray-based clinical testing via a core team of microarray-pioneering physicians, scientists and technicians and has a strong commitment to both client and patient-focused service.

BENCH will be used for the analysis, interpretation and reporting of microarray results in routine postnatal and prenatal settings. The flexible nature of the BENCH platform will allow it to be tailored to CombiMatrix's variant assessment and reporting workflow, significantly accelerating the interpretation and reporting process without disrupting the established operating procedures. Additionally, BENCH's architecture will allow integration and communication with existing IT systems at CombiMatrix.

Richard D. Hockett, Jr., M.D.,Chief Medical Officer at CombiMatrix remarked, "With our lab operations and test volumes growing, it made perfect sense to select the Cartagenia BENCH platform at this time. We already perform hundreds of microarray analyses per month and having recently expanded testing for the prenatal marketplace, that number will grow even more. The automation provided by BENCHlab CNV gives us the ability to grow our array throughput while providing significant savings in both analysis and interpretation time and staffing. Another deciding factor was that Cartagenia clearly positions its solutions for clinical use in contrast to other software packages."

"We are pleased and excited to be working with CombiMatrix," said Drew Arnold, Cartagenia's VP of Sales, North America. "Its selection of the BENCH platform is a strong validation of our approach and indicative of the efficiencies that BENCH can bring to diagnostic laboratories."

Cartagenia successfully went through the process of implementing an ISO-certified quality management system and has registered the BENCH platform for variant interpretation and reporting as a Class 1 Medical Device with the FDA.

"We want to provide a 'clinical grade' tool set to our customer and help labs building a reliable infrastructure for clinical use of high-throughput genomic technologies," Arnold added.

About Cartagenia

Cartagenia supplies diagnostic software, database systems, and related services to genetic labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and careers high-quality genetic interpretation and counseling.

The Cartagenia BENCH platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, BENCHlab CNV addresses the specific needs of genetic diagnostic labs and clinicians.

Cartagenia BENCHlab CNV is built using a certified ISO13485 Quality Management System and is marketed as an FDA regulated Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.

www.cartagenia.com

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory that offers DNA-based testing services to the prenatal, pediatric and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. CMDX was also the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Contact:
CARTAGENIA
Herman Verrelst
CEO Cartagenia
Technologielaan 3
3001 Leuven
T +32 16 40 40 66
E herman.verrelst@cartagenia.com
www.cartagenia.com

ALLEN & CARON
Len Hall
VP Media Relations
T 1 949 474 4300
E len@allencaron.com
www.allencaron.com


'/>"/>
SOURCE Cartagenia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
2. Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation
3. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
4. Luminex Corporation Reports Third Quarter 2012 Results
5. Unilife Corporation Reschedules Release Of Quarterly Results And Earnings Call Due To Severe Weather In Northeastern U.S.
6. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
7. Unilife Corporation To Announce Financial Results For Fiscal 2013 First Quarter On Tuesday, October 30, 2012
8. Harvest Technologies Corporation reicht Patentverletzungsklage gegen ThermoGenesis Corporation ein
9. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
10. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
11. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 (Kanadische ... http://www.sedar.com ) und der Website ... --> http://www.sedar.com ) und ... abrufbar.    --> Telesta ... Konzernabschluss des zweiten Quartals und die ...
(Date:2/12/2016)... HOUSTON , Feb. 12, 2016  Memorial Hermann ... center Dwight Howard to bring a one-of-a-kind ... Hospital . Using cutting-edge technologies such as 360-degree video ... kids both virtually, then literally – giving the patients ... – and it was all caught on video ...
(Date:2/12/2016)... INDIANAPOLIS , Feb. 12, 2016  Eli Lilly and ... High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent ... in the UK, France , ... instructions to dilute the product only with dextrose solution.  ... of 2015, the UK Court of Appeal held that Lilly,s ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Erlanger Agency ... the greater Columbus, OH area. The latest campaign focuses on the fight against breast ... Donations are now being accepted here . , Carmen is a loving single ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the ... and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the collaboration, ... facilities as a way to accommodate a more certain time frame for donor families ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet Lake, ... and dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry ... donating their time and skills to help hundreds of uninsured and underinsured people receive ...
(Date:2/12/2016)... New York, NY (PRWEB) , ... February 12, ... ... latest edition of “Revolutionizing Cancer Care.” , The print component of ... in Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar that will ... access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi ...
Breaking Medicine News(10 mins):